Puma Biotechnology Stock Today
| PBYI Stock | USD 5.02 0.14 2.87% |
Performance2 of 100
| Odds Of DistressLess than 9
|
Puma Biotechnology is trading at 5.02 as of the 28th of April 2024. This is a 2.87 percent up since the beginning of the trading day. The stock's open price was 4.88. Puma Biotechnology has less than a 9 % chance of experiencing financial distress in the next few years but had a somewhat weak performance during the last 90 days. Equity ratings for Puma Biotechnology are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of March 2024 and ending today, the 28th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 24th of April 2012 | Category Healthcare | Classification Health Care |
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company was founded in 2010 and is headquartered in Los Angeles, California. The company has 48.21 M outstanding shares of which 3.33 M shares are at this time shorted by private and institutional investors with about 6.14 trading days to cover. More on Puma Biotechnology
Moving together with Puma Stock
| 0.66 | VTRS | Viatris Earnings Call Next Week | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 2nd of May 2024
Puma Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Puma Biotechnology's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Puma Biotechnology or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Chairman | Alan Auerbach | ||||
| Thematic Idea | Cancer Fighters (View all Themes) | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation Analysts covering Puma Biotechnology report their recommendations after researching Puma Biotechnology's financial statements, talking to executives and customers, or listening in on Puma Biotechnology's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Puma Biotechnology. The Puma consensus assessment is calculated by taking the average forecast from all of the analysts covering Puma Biotechnology. | |||||
Puma Biotechnology's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Puma Biotechnology's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Puma Biotechnology's financial leverage. It provides some insight into what part of Puma Biotechnology's total assets is financed by creditors.
| |||||
Puma Biotechnology (PBYI) is traded on NASDAQ Exchange in USA. It is located in 10880 Wilshire Boulevard, Los Angeles, CA, United States, 90024 and employs 185 people. Puma Biotechnology is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 242 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Puma Biotechnology's market, we take the total number of its shares issued and multiply it by Puma Biotechnology's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Puma Biotechnology conducts business under Biotechnology sector and is part of Health Care industry. The entity has 48.21 M outstanding shares of which 3.33 M shares are at this time shorted by private and institutional investors with about 6.14 trading days to cover.
Puma Biotechnology currently holds about 77.96 M in cash with 27.01 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.71.
Check Puma Biotechnology Probability Of Bankruptcy
Ownership AllocationPuma Biotechnology has a total of 48.21 Million outstanding shares. Over half of Puma Biotechnology's outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulations than regular investors in Puma Biotechnology. Please watch out for any change in the institutional holdings of Puma Biotechnology as this could mean something significant has changed or is about to change at the company. Note that regardless of who owns the company, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns over time.
Check Puma Ownership Details
Puma Stock Price Odds Analysis
Coming from a normal probability distribution, the odds of Puma Biotechnology jumping above the current price in 90 days from now is about 76.04%. The Puma Biotechnology probability density function shows the probability of Puma Biotechnology stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 2.0073 indicating as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Puma Biotechnology will likely underperform. Additionally, puma Biotechnology has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Puma Biotechnology to move above the current price in 90 days from now is about 76.04 (This Puma Biotechnology probability density function shows the probability of Puma Stock to fall within a particular range of prices over 90 days) .
Puma Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Puma Biotechnology that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Puma Biotechnology's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Puma Biotechnology's value.| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2023-12-31 | 444 K | |
| Morgan Stanley - Brokerage Accounts | 2023-12-31 | 376.3 K | |
| Marshall Wace Asset Management Ltd | 2023-12-31 | 348.6 K | |
| Rice Hall James & Associates, Llc | 2023-12-31 | 329.9 K | |
| Sei Investments Co | 2023-12-31 | 291.9 K | |
| Two Sigma Advisers, Llc | 2023-12-31 | 284.8 K | |
| Gsa Capital Partners Llp | 2023-12-31 | 262.3 K | |
| Goldman Sachs Group Inc | 2023-12-31 | 231.9 K | |
| Two Sigma Investments Llc | 2023-12-31 | 215.2 K | |
| Vanguard Group Inc | 2023-12-31 | 3.8 M | |
| Millennium Management Llc | 2023-12-31 | 3.2 M |
Puma Biotechnology Historical Income Statement
Puma Biotechnology Income Statement is one of the three primary financial statements used for reporting Puma's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Puma Biotechnology revenue and expense. Puma Biotechnology Income Statement primarily focuses on the company's revenues and expenses during a particular period.
As of now, Puma Biotechnology's EBITDA is increasing as compared to previous years. The Puma Biotechnology's current Total Operating Expenses is estimated to increase to about 153.3 M, while Other Operating Expenses is projected to decrease to under 174.6 M. View More FundamentalsPuma Stock Against Markets
Picking the right benchmark for Puma Biotechnology stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Puma Biotechnology stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Puma Biotechnology is critical whether you are bullish or bearish towards Puma Biotechnology at a given time. Please also check how Puma Biotechnology's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Puma Biotechnology without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Money Flow Index Now
Money Flow IndexDetermine momentum by analyzing Money Flow Index and other technical indicators |
| All Next | Launch Module |
Puma Biotechnology Corporate Directors
Puma Biotechnology corporate directors refer to members of a Puma Biotechnology board of directors. The board of directors generally takes responsibility for the Puma Biotechnology's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Puma Biotechnology's board members must vote for the resolution. The Puma Biotechnology board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Troy Wilson | Director | Profile | |
| Michael Miller | Director | Profile | |
| Adrian Senderowicz | Director | Profile | |
| Mariann Ohanesian | Senior Director, Investor Relations | Profile |
How to buy Puma Stock?
Before investing in Puma Biotechnology, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Puma Biotechnology. To buy Puma Biotechnology stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Puma Biotechnology. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Puma Biotechnology stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Puma Biotechnology stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Puma Biotechnology stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Puma Biotechnology, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Puma Stock please use our How to Invest in Puma Biotechnology guide.
Already Invested in Puma Biotechnology?
The danger of trading Puma Biotechnology is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Puma Biotechnology is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Puma Biotechnology. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Puma Biotechnology is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Puma Biotechnology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Puma Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Puma Biotechnology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Puma Biotechnology Stock: Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Puma Biotechnology. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing. For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Complementary Tools for Puma Stock analysis
When running Puma Biotechnology's price analysis, check to measure Puma Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Puma Biotechnology is operating at the current time. Most of Puma Biotechnology's value examination focuses on studying past and present price action to predict the probability of Puma Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Puma Biotechnology's price. Additionally, you may evaluate how the addition of Puma Biotechnology to your portfolios can decrease your overall portfolio volatility.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |
Is Puma Biotechnology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Puma Biotechnology. If investors know Puma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Puma Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.78) | Earnings Share 0.45 | Revenue Per Share 4.999 | Quarterly Revenue Growth 0.099 | Return On Assets 0.0919 |
The market value of Puma Biotechnology is measured differently than its book value, which is the value of Puma that is recorded on the company's balance sheet. Investors also form their own opinion of Puma Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Puma Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Puma Biotechnology's market value can be influenced by many factors that don't directly affect Puma Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Puma Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Puma Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Puma Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.